BeiGene, Ltd.

Equities

BGNE

US07725L1026

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 11:38:12 2024-04-12 am EDT 5-day change 1st Jan Change
143.9 USD -1.53% Intraday chart for BeiGene, Ltd. -4.29% -20.39%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech MT
BeiGene Opens New Factory in Guangzhou for Antibody-Drug Conjugates MT
Beigene Shrinks Loss by 56% in 2023 MT
Bernstein Adjusts BeiGene's Price Target to $161 From $196, Maintains Market Perform Rating MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading MT
BeiGene, Ltd. Announces Executive Changes CI
Beigene's Esophageal Cancer Drug Gets US FDA Nod MT
Beigene Insider Sold Shares Worth $8,368,017, According to a Recent SEC Filing MT
BeiGene Says FDA Approves Tevimbra to Treat Some Esophageal Cancer Patients DJ
BeiGene Gets FDA Approval for Esophageal Cancer Treatment MT
BeiGene, Ltd. Receives FDA Approval for TEVIMBRA for Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy CI
US FDA approves BeiGene's esophageal cancer therapy RE
BeiGene Sells Over 1 Million Underlying Shares Under Purchase Plan MT
Asian Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading MT
BeiGene, Max Foundation Providing Brukinsa to Leukemia Patients in Armenia, Nepal as Part of 3-Year Partnership MT
BeiGene Shares Rise on First Dosing of Brukinsa DJ
BeiGene Gets FDA's Accelerated Approval for Follicular Lymphoma Treatment MT
BeiGene, Ltd. Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma CI
US FDA approves expanded use of BeiGene's blood cancer drug RE
BeiGene, Ltd. to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024 CI
BeiGene's Pi Health Units to Merge MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading MT
BeiGene Says FDA Accepts License Application For Tevimbra For Gastric Cancers MT
BeiGene’s Non-Small Cell Lung Cancer Drug Gets Recommended for Approval by European Regulator MT
Chart BeiGene, Ltd.
More charts
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
146.1 USD
Average target price
268.6 USD
Spread / Average Target
+83.84%
Consensus
  1. Stock Market
  2. Equities
  3. BGNE Stock
  4. News BeiGene, Ltd.
  5. BeiGene Says Cancer Treatment Label Update Gets Approved by FDA